{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-036307","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.513143+00:00","generated_at":"2026-06-26T21:00:40.592597+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Voyager Therapeutics appoints Alfred Sandrock as President and CEO, effective March 22, 2022","bullets":["Alfred Sandrock, former Biogen EVP of R&D, appointed President and CEO effective March 22, 2022.","Sandrock receives base salary of $600,000, signing bonus of $50,000, target annual bonus of 55% of base salary.","Equity grants: stock option for 940,600 shares and RSU for 100,000 shares, both vesting over four years.","Michael Higgins ceases as Interim CEO, remains Chairman and independent director; receives $30,000 transition retainer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-036307","json":"https://secwatch.observer/filing/0001104659-22-036307.json","markdown":"https://secwatch.observer/filing/0001104659-22-036307.md","text":"https://secwatch.observer/filing/0001104659-22-036307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922036307/0001104659-22-036307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922036307/tm229951d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:00:40.592597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa969e331b","claim":"Alfred Sandrock was appointed as President and Chief Executive Officer at Voyager Therapeutics, Inc..","evidence_excerpt":"Appointment of Alfred Sandrock, M.D., Ph.D. as President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922036307/0001104659-22-036307-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}